Publications by authors named "Jacob Tanguay"

Claim this Profile
M
Metformin for patients with metastatic prostate cancer starting androgen deprivation therapy: a randomised phase 3 trial of the STAMPEDE platform protocol.
Silke Gillessen, Laura Murphy, Nicholas D James, Ashwin Sachdeva, Omar El-Taji, Jacob S Tanguay

Lancet Oncol· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Abiraterone acetate plus prednisolone with or without enzalutamide for patients with metastatic prostate cancer starting androgen deprivation therapy: final results from two randomised phase 3 trials of the STAMPEDE platform protocol.
Gerhardt Attard, Laura Murphy, Noel W Clarke, Ashwin Sachdeva, Craig Jones, Jacob Tanguay

Lancet Oncol· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Abiraterone acetate plus prednisolone for metastatic patients starting hormone therapy: 5-year follow-up results from the STAMPEDE randomised trial (NCT00268476).
Nicholas D James, Noel W Clarke, Adrian Cook, Adnan Ali, Alex P Hoyle, Jacob S Tanguay

Int J Cancer· August 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Docetaxel for Nonmetastatic Prostate Cancer: Long-Term Survival Outcomes in the STAMPEDE Randomized Controlled Trial.
Nicholas D James, Fiona C Ingleby, Noel W Clarke, Claire L Amos, Gerhardt Attard, Jacob S Tanguay

JNCI Cancer Spectr· July 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Radiotherapy to the prostate for men with metastatic prostate cancer in the UK and Switzerland: Long-term results from the STAMPEDE randomised controlled trial.
Chris C Parker, Nicholas D James, Christopher D Brawley, Noel W Clarke, Adnan Ali, Jacob Tanguay

PLoS Med· June 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
Q
Quality of Life in Men With Prostate Cancer Randomly Allocated to Receive Docetaxel or Abiraterone in the STAMPEDE Trial.
Hannah L Rush, Laura Murphy, Alicia K Morgans, Noel W Clarke, Adrian D Cook, Jacob S Tanguay

J Clin Oncol· March 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Abiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer: a meta-analysis of primary results from two randomised controlled phase 3 trials of the STAMPEDE platform protocol.
Gerhardt Attard, Laura Murphy, Noel W Clarke, William Cross, Robert J Jones, Jacob Tanguay

Lancet· January 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): a multicentre, open-label, randomised, phase 2 trial.
Joaquin Mateo, Nuria Porta, Diletta Bianchini, Ursula McGovern, Tony Elliott, Jacob Tanguay

Lancet Oncol· January 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Assessment of the feasibility of using transrectal ultrasound for postimplant dosimetry in low-dose-rate prostate brachytherapy.
Rhian Siân Davies, Teresa Perrett, Jane Powell, Jim Barber, Jacob Tanguay

Med Dosim· August 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
W
What Predicts Minimal Response to Abiraterone in Metastatic Castrate-resistant Prostate Cancer?
Rhian Siân Davies, Christian Smith, Michael Robert Button, Jacob Tanguay, Jim Barber

Anticancer Res· October 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Time to prostate specific antigen (PSA) nadir may predict rapid relapse in men with metastatic castration-resistant prostate cancer (CRPC) receiving docetaxel chemotherapy.
Betsan M Thomas, Christian Smith, Jessica Evans, Michael R Button, Satish Kumar, Jacob S Tanguay

Med Oncol· December 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Docetaxel chemotherapy for metastatic hormone refractory prostate cancer as first-line palliative chemotherapy and subsequent re-treatment: Birmingham experience.
Jawaher Ansari, Syed Anwer Hussain, Anjali Zarkar, Jacob S Tanguay, Julie Bliss

Oncol Rep· October 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis